MHDL Updates

1. Additions
   Effective May 30, 2017, the following newly marketed drugs have been added to the MassHealth Drug List.
   - Arymo ER (morphine extended-release tablet) – PA
   - ergotamine – PA
   - Eucrisa (crisaborole) – PA
   - Siliq (brodalumab) – PA
   - Trulance (plecanatide) – PA

2. Change in Prior-Authorization Status
   a. Effective May 30, 2017, the following gastrointestinal anti-inflammatory agents will require prior authorization.
      - Dipentum (olsalazine) – PA
      - Pentasa (mesalamine controlled-release) – PA
   b. Effective May 30, 2017, the following ergot alkaloid agents will require prior authorization.
      - D.H.E. 45 (dihydroergotamine injection) – PA
      - ergotamine/caffeine tablet – PA
      - ergotamine/caffeine suppository – PA
   c. Effective May 30, 2017, the following kinase inhibitor will require prior authorization.
      - Votrient (pazopanib) – PA

Footnotes:

PA Prior authorization is required. The prescriber must obtain prior authorization for the drug in order for the pharmacy to receive payment. Note: Prior authorization applies to both the brand-name and the FDA “A”-rated generic equivalent of listed product.

# This designates a brand-name drug with FDA “A”-rated generic equivalents. Prior authorization is required for the brand, unless a particular form of that drug (for example, tablet, capsule, or liquid) does not have an FDA “A”-rated generic equivalent.

BP Brand Preferred over generic equivalents. In general, MassHealth requires a trial of the preferred drug or clinical rationale for prescribing the non-preferred drug generic equivalent.

* The generic OTC and, if any, generic prescription versions of the drug are payable under MassHealth without prior authorization.

^ This drug is available through the health care professional who administers the drug. MassHealth does not pay for this drug to be dispensed through a retail pharmacy.

Please direct any questions or comments (or to be taken off of this fax distribution) to Victor Moquin of Xerox at 617-423-9830.